<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130813014350N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-06</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of injection of platelet-rich fibrin gel and hyaluronic acid filler on interdental papilla reconstruction, a randomized clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of injection of platelet-rich fibrin gel (Alb-PRF) and hyaluronic acid filler on interdental papilla reconstruction, a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>33</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62723</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization method with 4 and 6 block sizes will be performed in both intervention and control groups. It should be noted that if the patient has more than one eligible incomplete papilla, these papillae are assigned to the same treatment group. Random allocation sequence generation is done using the site www.sealedenvelope.com.
Allocation concealment is performed using opaque numbered, stamped and sealed randomly sequenced (SNOSE) envelopes, Blinding description: This test will be double-blinded. In this study, due to blood sampling in one group, it is not possible to blind the patient, and in any case, the patient will know in which group he will be studied. Also, due to the apparent difference between the two substances and the Alb-PRF preparation, it is not possible to blind the sample allocator. Therefore, in the present study, the outcome evaluator is not aware of the injectable substance in each papilla. Also, the analyst of the study results will not know about the study groups. A code will be assigned to each of the treated papillae for statistical analysis.</study_design>
      <phase>N/A</phase>
      <hc_freetext>reconstruction of incomplete interdental papilla.</hc_freetext>
      <i_freetext>Intervention 1: The treatment protocol was divided into 3 stages: pre-injection stage, or examination, injection stage and follow-up stage.The first visit will begin with the collection of demographic information, medical history and dentistry. Conscious consent is signed by patients. Primary periodontal treatment includes scaling and debridement of the gums. Plaque index is recorded in the teeth of the treated area. The distance between the tooth contact and the bone crest is measured by parallel periapical radiography. Before starting the test, the interdental papilla is evaluated according to the Nordland and Tarnow classifications and will be recorded in the relevant tables. Clinical photographs perpendicular to the target teeth will also be taken. Black triangles are measured clinically from the tip of the papilla to the point of interdental contact using a Williams periodontal probe and an acrylic stent...Intervention group: Hyaluronic acid filler injection............ After injection of local anesthesia, a hyaluronic acid filler with an approximate amount of less than 0.2 ml, 2-3 mm apical from the papilla tip and at an angle of 45 degrees to the longitudinal axis of the tooth will be injected with a 30 gauge insulin syringe. Patients will then be instructed in oral and written care after the injection. Patients are recalled in for a booster dose three weeks later. Intervention 2: Intervention group: Platelet-rich fibrin gel injection.......Preparation of Alb-PRF:From each patient, 9 ml of whole blood is collected in a plastic tube and immediately centrifuged at 700 g at room temperature for 8 minutes. After centrifugation, the top 2 ml layer (PPP) is collected in 2 ml syringes and heated at 75 ° C for 10 minutes to prepare a denatured albumin gel. The tube is then allowed to reach room temperature again for 10 minutes. Liquid PRF (layer on RBC) containing residual cells and growth factors is mixed with albumin gel and Alb-PRF gel is prepared ready for injection.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Comparison of the effect of injection of platelet-rich fibrin gel and hyaluronic acid filler on interdental papilla reconstruction, a randomized clinical trial

When:
6-12 months after result publication

To whom:
Researchers working in academic institutions

Conditions:
Use in higher level studies such as systematic review studies

Where to obtain:
ا Bardia@gums.ac.ir

How to obtain:
Documents for writing a review article (for example, an invitation letter from the journal) should be provided

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bardia Vadiati Saberi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Saravan-Fouman road</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4188794755</zip>
        <telephone>+98 13 1326 3622</telephone>
        <email>bardia@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bardia Vadiati Saberi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Saravan-Fouman road</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4194173774</zip>
        <telephone>+98 13 1326 3622</telephone>
        <email>bardia@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Written informed consent to participate in the study
Having at least one deficient papilla
Class I or II papillary defects according to the Nordland and Tarnow classifications
Probing depth ≤4 mm
Age between 20-75</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Gingivitis or periodontitis
Diabetes, connective tissue diseases and other systemic diseases affecting periodontal tissues
History of allergic reaction
Pregnant and lactating women
History of periodontal surgery in the area in the last 6 months
Open contact (diastem) in the area
Medications that cause gingival hyperplasia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K06.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Gingival recession</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The treatment protocol was divided into 3 stages: pre-injection stage, or examination, injection stage and follow-up stage.The first visit will begin with the collection of demographic information, medical history and dentistry. Conscious consent is signed by patients. Primary periodontal treatment includes scaling and debridement of the gums. Plaque index is recorded in the teeth of the treated area. The distance between the tooth contact and the bone crest is measured by parallel periapical radiography. Before starting the test, the interdental papilla is evaluated according to the Nordland and Tarnow classifications and will be recorded in the relevant tables. Clinical photographs perpendicular to the target teeth will also be taken. Black triangles are measured clinically from the tip of the papilla to the point of interdental contact using a Williams periodontal probe and an acrylic stent...Intervention group: Hyaluronic acid filler injection............ After injection of local anesthesia, a hyaluronic acid filler with an approximate amount of less than 0.2 ml, 2-3 mm apical from the papilla tip and at an angle of 45 degrees to the longitudinal axis of the tooth will be injected with a 30 gauge insulin syringe. Patients will then be instructed in oral and written care after the injection. Patients are recalled in for a booster dose three weeks later.</i_keyword>
      <i_keyword>Intervention group: Platelet-rich fibrin gel injection.......Preparation of Alb-PRF:From each patient, 9 ml of whole blood is collected in a plastic tube and immediately centrifuged at 700 g at room temperature for 8 minutes. After centrifugation, the top 2 ml layer (PPP) is collected in 2 ml syringes and heated at 75 ° C for 10 minutes to prepare a denatured albumin gel. The tube is then allowed to reach room temperature again for 10 minutes. Liquid PRF (layer on RBC) containing residual cells and growth factors is mixed with albumin gel and Alb-PRF gel is prepared ready for injection.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Interdental papilla fill (black triangle area change). Timepoint: 0, 3, 6 months. Method of measurement: Measure the area of black triangles at specified intervals and examine the area changes in Photoshop.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patients' satisfaction with the results of the intervention. Timepoint: at the end of the sixth month. Method of measurement: visual analogue scale.</sec_outcome>
      <sec_outcome>Plaque index on the treated teeth. Timepoint: At the beginning and end of the study (0 and 6 months). Method of measurement: Loe index, the amount of microbial plaque accumulated on the treated teeth (especially in the interproximal area).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dental Research Centre, Guilan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-03-10</approval_date>
        <contact_name>Ethics committee of guilan University of Medical Sciences</contact_name>
        <contact_address>Bustan Mellat, Ahmadzadeh Blvd., Shahid Amini Alley, Parvaneh dead end, No. 103, Rose Building Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
